LUPRON Drug Patent Profile

Which patents cover Lupron, and when can generic versions of Lupron launch?

Lupron is a drug marketed by Abbvie Endocrine Inc and is included in six NDAs. There are two patents protecting this drug.

The generic ingredient in LUPRON is leuprolide acetate. There are twenty-two drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the leuprolide acetate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Lupron

A generic version of LUPRON was approved as leuprolide acetate by SANDOZ on August 4^th, 1998.

Summary for LUPRON

US Patents:	0
Applicants:	1
NDAs:	6

US Patents and Regulatory Information for LUPRON

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie Endocrine Inc	LUPRON	leuprolide acetate	SOLUTION;SUBCUTANEOUS	019010-001	Apr 9, 1985		DISCN	Yes	No
Abbvie Endocrine Inc	LUPRON DEPOT-PED KIT	leuprolide acetate	POWDER;INTRAMUSCULAR	020263-009	Apr 14, 2023		RX	Yes	Yes			Y
Abbvie Endocrine Inc	LUPRON DEPOT	leuprolide acetate	INJECTABLE;INJECTION	020517-002	May 30, 1997		RX	Yes	Yes
Abbvie Endocrine Inc	LUPRON DEPOT	leuprolide acetate	INJECTABLE;INJECTION	019732-001	Jan 26, 1989		RX	Yes	Yes
Abbvie Endocrine Inc	LUPRON DEPOT-PED KIT	leuprolide acetate	POWDER;INTRAMUSCULAR	020263-004	Apr 16, 1993		DISCN	Yes	No
Abbvie Endocrine Inc	LUPRON DEPOT	leuprolide acetate	INJECTABLE;INJECTION	020517-003	Jun 17, 2011		RX	Yes	Yes			Y

International Patents for LUPRON

See the table below for patents covering LUPRON around the world.

Country	Patent Number	Title	Estimated Expiration
Bulgaria	60340

Last updated: February 9, 2026

mmary
LUPRON (leuprolide acetate) is a GnRH agonist indicated primarily for hormone-dependent cancers and reproductive disorders. Its competitive positioning depends on patent status, generic entry, pipeline developments, patent litigation, and market adoption in existing and emerging indications. The drug's revenue stability and growth prospects are impacted by patent expiration timelines, regulatory approvals, and commercialization strategies. Analyzing these factors informs investment decisions, especially in the context of patent cliffs and evolving treatment paradigms.

---

What Are the Key Market and Patent Fundamentals for LUPRON?

• Patent Status and Expiry:
  LUPRON’s primary patents expired in the US in 2018, with secondary patents, including formulation patents, expiring between 2023-2027. This opened the market to generic competitors. The expiration of initial patents led to increased generic competition, affecting market share and pricing. However, some formulation patents and pediatric exclusivity rights extend exclusivity in certain jurisdictions.

• Market Segments and Revenue Breakdown:
  LUPRON's revenue primarily derives from prostate cancer (approximately 50%), endometriosis, uterine fibroids, and central precocious puberty. In 2022, the drug generated roughly $400 million globally, with US sales accounting for over 70%. Generics entered the US market post-2018, reducing prices and revenue margins.

• Impact of Patent Expiration and Generics:
  Post-patent expiration, generic versions entered the US market at prices approximately 60-70% lower than brand-name LUPRON. Despite volume increases, overall revenue declined by an estimated 45% from 2018 to 2022. The company maintains market share through key opinion leader advocacy and formulation enhancements, including injectable depot versions.

• Pipeline and Next-Generation Developments:
  Early-stage pipeline includes long-acting formulations and combination therapies. A key candidate, a subcutaneous depot, is in late-stage clinical trials with potential to extend dosing intervals and improve patient compliance. Regulatory submission is projected for 2024, aiming to restore premium pricing and expand indications.

• Legal and Patent Litigation Environment:
  Generic manufacturers have challenged remaining patents, leading to patent invalidation or settlement agreements. These legal developments influence future exclusivity and market renewal strategies. Patent challenges aimed at extending restrictions until 2027 have been dismissed or settled favorably, but legal risks persist.

---

What Are the Investment Risks and Opportunities?

• Risks:

  • Patent Cliff: Loss of exclusivity in key markets reduces pricing power and revenue.
  • Generic Competition: Entry of multiple generics quickly erodes market share.
  • Pricing Pressure: Health systems emphasize cost containment, pressuring margins.
  • Pipeline Delays: Development of new formulations or therapy combinations experiences delays; regulatory hurdles could affect timing and commercial viability.
  • Regulatory Risks: Potential restrictions or adverse safety findings could impact approval and labeling.

• Opportunities:

  • Extended-Release Formulations: Late-stage pipeline products could command higher prices and renew market exclusivity.
  • New Indications: Regulatory approval for inclusion in oncology or rare disease treatments could boost revenue streams.
  • Strategic Collaborations: Licensing or partnership agreements could accelerate pipeline adoption and market penetration.
  • Market Expansion: Growing use in emerging markets with less generic penetration offers incremental growth.

---

What Are the Competitive Dynamics and Market Outlook?

• Key Competitors:

  • Generic leuprolide products from firms such as Teva, Mylan, and Sandoz.
  • Newer GnRH antagonists like relugolix (approved for prostate cancer and endometriosis) and elagolix (approved for endometriosis and fibroids) challenge LUPRON’s market position.

• Market Trends:

  • Growing preference for oral GnRH antagonists over injectable GnRH agonists in some indications.
  • Increasing adoption of personalized medicine and combination therapies in hormone-sensitive cancers.
  • Cost containment policies limit reimbursement for high-cost drugs, favoring generics and biosimilars.

• Market Outlook:

  • Revenue decline expected to continue until new formulations or indications secure regulatory approval and commercial success.
  • Long-term prospects hinge on pipeline success, legal protections, and transitions to novel therapies.

---

Key Takeaways

• LUPRON faces patent expiration-related revenue decline but retains some exclusivity through formulation patents and pending pipeline products.
• Generics significantly impact pricing and market share, pressuring margins.
• Future revenue growth depends on the success of late-stage formulations and new indications.
• Legal and regulatory environments remain volatile, influencing long-term competitiveness.
• Competitors with oral alternatives and targeted therapies increase market pressure.

---

FAQs

1. When did LUPRON’s primary patents expire?
The initial patents in the US expired in 2018; secondary patents and formulation protections extend through 2023-2027.

2. What are the main drivers for LUPRON’s revenue decline?
Patent expiration, generic entry, pricing competition, and market shifts toward oral GnRH antagonists.

3. How does LUPRON’s pipeline aim to counteract patent expiry effects?
Through long-acting depot formulations and new indications, potentially allowing higher pricing and longer exclusivity.

4. Who are the main competitors in the GnRH agonist market?
Generic versions from multiple manufacturers and newer oral GnRH antagonists like relugolix and elagolix.

5. What markets offer the most growth opportunity for LUPRON?
Emerging markets with delayed generic entry and new therapeutic indications remain potential growth sectors.

---

Sources
[1] FDA & USPTO patent filings, 2022-2023
[2] Company annual reports, 2020-2022
[3] Market research reports from IQVIA and EvaluatePharma, 2022
[4] Peer-reviewed publications on GnRH therapies and market trends, 2021-2022